News
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...
The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...
The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...
6h
Zacks Investment Research on MSNNovartis Beats on Q2 Earnings and Sales, CFO Retires, Stock DownSwiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
A new type of medical treatment is scheduled to travel the highways and byways from headquarters in Temple in an effort to ...
“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer ...
In mice bearing Pluvicto-failed tumors, ATNM-400 was administered on day 14 following Pluvicto treatment, demonstrating robust antitumor activity and tumor growth inhibition in Pluvicto- resistant ...
Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC 1. Novartis is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results